Rationale, aims, and objectives Colorectal cancer (CRC) screening is widely recommended and implemented. However, sometimes CRC screening is not implemented despite good evidence, and some types of CRC screening are implemented despite lack of evidence. The Results A wide range of important ethical issues were identified. The main benefits are reduced relative CRC mortality rate, and potentially incidence rate, but there is no evidence of reduced absolute mortality rate. Potential harms are bleeding, perforation, false test results, overdetection, overdiagnosis, overtreatment (including unnecessary removal of polyps), and (rarely) death. Other important issues are related to autonomy and informed choice equity, justice, medicalization, and expanding disease. 
trained in HTA and ethics and grouped in accordance with their content. Identified issues that were not addressed by any questions were highlighted, and questions not covered by any identified issues were scrutinized with supplementary searches to see if there are ethical issues that have not been identified by the literature. These supplementary efforts are based on training in ethics.
As the approach aims at comprehensiveness in covering all ethical issues, and not at exhaustiveness in identifying all references addressing the same issue, only seminal references were included for the same issue. References only mentioning that there are ethical issues without providing any substance or analysis of the issue(s) were excluded.
| RESULTS
The results from the literature search are illustrated in Figure 1 .
| Benefits, burdens, and harms
The CRC is a type of cancer that develops relatively slow and thus is well suited for screening. Benefits and harm will depend on uptake, skills, and organizing of screening program, ie, on context. One such contextual evidence compilation (for Norway) is shown in Table 1 .
None of the methods has demonstrated a reduction in the overall mortality rate. 9 False reassurance due to screening is suggested as one reason for the discrepancy between reduction in relative and absolute mortality rate [10] [11] [12] and that screening "does not actually save lives but shifts individuals to other causes of mortality" is another.
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| Benefits
The main benefits are identified as reduced CRC mortality and reduced disease incidence (for sigmoidoscopy). Table 1 shows the estimated number of deaths avoided. In addition, some may also experience reduced anxiety and health reassurance, resulting from CRC screening. 14 Endoscopic screening also avoids some of the challenges with other screening programs, such as anxiety, because detection, diagnosis, and treatment can be delivered at the same time. 15 The benefits have made several international and national organizations to recommend CRC screening, which is considered by many to be an ethical imperative. 16 
| Harms
As seen in Table 1 , bleeding, perforation, and death are potential harms, resulting from (subsequent) endoscopic procedures. Severe bleeding resulting from (subsequent) colonoscopy is observed in 0% to 0.2% of patients. 17 The risk of death is estimated to be 0.002 % for colonoscopy. 9 Other identified harms are false test results (negative and positive), overdetection, overdiagnosis, overtreatment, and adverse effects of such diagnostics and treatment. False positive test results generate a risk of people having to undergo unnecessary diagnostic FIGURE 1 Flowchart over results from literature search tests and may generate worries of having a disease that is not present 18 and can result in reduced adherence. 19 False-negative test results can give rise to false reassurance and thereby possible ignorance of future symptoms of cancer, ultimately resulting in delayed diagnosis 20 and poorer outcomes.
Overdiagnosis is rarely assessed. Only 1 study has assessed overdiagnosis for early detection in CRC screening and estimated an overdiagnosis rate of 0.1% to 0.9%. 21 The reason for this may be that the main focus has been prevention and not early detection and the definition of overdiagnosis. By only including manifest CRC in the definition of overdiagnosis, the numbers will be small. However, if one would include all polyps acted on (which would not evolve to manifest CRC) the overdiagnosis rates would be much higher.
Prevention CRC screening aims at identifying and removing precursors of disease. However, most resected colonic polyps would not have otherwise caused morbidity or death as they would not advance to disease, and many of them would regress. 22 Identification and removal of such lesions represents overdetection and overtreatment, respectively, and the overdetection ("overreporting" and "oversurveillance") and overtreatment rate is substantial as most of the identified lesions would not have developed to CRC if they were not detected, and the trend is to find ever smaller lesions. 23 However, polypectomy is considered to be far less invasive and cumbersome than the treatment of cancer and therefore considered to be less morally challenging. 5 Nonetheless, it has been pointed out that CRC screening can inflict psychological distress on persons screened and be a source of subsantial costs and cage capacity. 5 However, no calculations of such costs have been identified. The detection and removal rate of nonadvanced adenomas is strongly increasing. 23 While this is done to decrease the number of interval cancers and the CRC mortality rate, it comes at the cost of a substantial increase in unnecessary detection and removal of adenomas. Hence, overuse and underuse have been identified 24 as moral problems, and it has been argued that improved survival is associated with improvement in treatment as much as with early detection.
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The main burdens are related to (endoscopic) examinations. Moderate or severe abdominal pain after colonoscopy are reported to be common for persons examined with standard air insufflation (16.6%) and less so with carbon dioxide (CO2) insufflation (4%). 17 There has also been a worry about CRC screening having a negative effect on lifestyle in general, 11, 26 The very different characteristics of the various screening tests prompt the question of whether invitees should be able to choose which screening method they find most appropriate according to their preferences. 58, 59 Choice of CRC screening method varies, and one large study found that patients who were offered an informed choice for screening had higher adherence rates than patients who were not offered a choice of screening test. 60 On the other hand, a minority of persons being screened report to have been asked about their preferences, 61 and attention to preferences may influence adherence.
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Knowledge of CRC screening is also very variable, 63 and a great number of invited persons do not make informed decisions about screening. 64 Information may overstate benefits 65 probably to increase uptake. 5 Accordingly, the quality of informed consent has been demonstrated to be low. 66 Nonetheless, people tend to want to be informed about risks. 67 Informed decision making may reduce the participation in screening. 68, 69 Therefore, nudging and biased information has been suggested for CRC surveillance, 70 and also for screening. 71 Ways to try to counterbalance "optimistic bias" have also been suggested (see below). 72 However, nudging and biased information is controversial as it breaches with standard conceptions of the principle of autonomy. Correspondingly, incentives may increase uptake of CRC screening, 73 but has been rejected on moral grounds. 74 Providing balanced information has been identified as a substantial challenge. 75, 76 One of the reasons for the challenges with informing about CRC screening is the (previously mentioned) complexity, and because it is hard to relate populational data to individuals and because of what has been called the "prevention paradox," ie, that although the screening will be of significant benefit to the population as a whole the individual's decision to get screened regularly may only have a small impact on that individual's risk of disease in the near future. 77 Even personalized quantitative CRC risk information is shown to have different effects on individuals, 78 making personal targeting difficult. Moreover, enthusiasm has incited biased information. 79 Accordingly, there may be many barriers to making informed choice, both personal (for potential participants) 57 and professional. 80 Crucial information is not always available, such as on overdiagnosis (early detection) and number of polyps detected and removed without benefit (overdetection and overtreatment with preventive screening).
Moreover, for screening programs with initial noninvasive screening tests information about subsequent invasive tests may reduce uptake, posing an ethical dilemma. 81 Another challenge is that people typically believe their health risks are lower than those of others (ie, optimistic bias). 82 Yet another psychological effect is defensive information processing about CRC screening. 83 A wide range of measures to improve information to participants and increase informed consent have been suggested and tested. 65, 72, [84] [85] [86] [87] [88] [89] [90] [91] These may cause dilemmas of their own, for example, targeting information to African Americans implies the risk of making people aware of disparities and disadvantages. 92 Lack of awareness and misconceptions are identified as reasons for lack of outcome from actions against CRC. 93 As information may result in anxiety 28 or "cancer information overload," this poses a moral dilemma. However, ways of informing may reduce the risk of anxiety and overload, and contextual sensitivity appears to be important. 94 On the other hand, some persons view participation as accepting an offer, where being informed does not impact on participation rates. 51 Moreover, different groups may have very different needs for information, 95, 96 and it can be difficult to predict their information preferences. 97 Hence, providing relevant information may be challenging and resource demanding. 98 Knowledge about the efficiency of the various methods for promoting informed consent is limited, and no one method appears to stand out in efficiency.
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| Practical challenges with screening-ethical implications
Due to the many options, optimizing screening strategies is identified as a chief challenge. 34 Tailoring the frequency of screening and limiting intervention for polyps that are not believed to be precursors to morbid disease have been key practical challenges with moral connotations. 22 So is providing risk-based personalized screening. 100 How to assess and balance the various CRC screening strategies is demanding. Evidence for gFOBT and sigmoidoscopy is available, while
we still have to wait many years for high-quality results from comparative studies with iFOBT and colonoscopy. 9 Whether one should introduce CRC screening programs with one or more of the tests where high-quality evidence is available, or whether to introduce alternative promising screening strategies on the basis of preliminary evidence (and modeling), or whether to set up screening programs as (long lasting and costly) scientific studies poses significant moral quandary. In the latter case, also which design to use and which screening tests to include. Moreover, offering gFOBT as one of the arms in a study could breach the criteria for equipoise (in research ethics).
Other practical issues, such as specific staffing, financial, and train- Accordingly, equity and equal access are important moral issues.
So is the question of how to balance equity and efficiency. Some studies show that equity trumps efficiency, 139 ie, that equal access to screening with respect to sex and age is considered to be more important than to select those groups where screening is most efficient (independent of sex and age).
| Justice
Studies show less effect of CRC screening with women. 140, 141 This raises the question of how to provide just screening programs for men and women. The same challenge exists for age, as the number of polyps increase significantly at the age 55 to 70 while CRC incidence increases at age 65 to 70. This makes it challenging to set lower and upper age limit. 142, 143 At the same time, screening risks may increase for older persons, 144, 145 while the capacity to adhere to test preparations may decrease 146 and to consent may decrease in older persons.
However, whether age is a selection criterion is contested. 147, 148 Various groups may also differ significantly in risk, 100, 149 and there are differences in how various groups experience burdens of endoscopy. "Mathematically just" may appear "emotionally unjust" in the population. Hence, which group to offer screening (and where to set limits, eg, to age and cut-offs) poses significant ethical challenges which are important for decision makers and health policy makers implementing screening programs. On the other hand, CRC does not have a strong social gradient and is not suitable for evening the playing field, 150 ie, to reduce the differences in health.
If screening programs drain resources from cancer surveillance and treatment it may pose ethical challenges (with respect to priority setting). This is especially problematic for high rates of overdetection and overuse. Another identified issue is that insurance companies may restrict insurance or increase insurance premium, as a positive test result may indicate an increased risk of disease. 151 At a more general level, whether it is right to use resources on health services for many healthy people for a condition that only relevant for a small fraction of the population (4%), 24,150 where there is a significant delay before results are experienced (10-15 years), 152 and where there is no overall reduction of mortality, while relevant alternatives exist 153 is a key moral question.
| The ethics of evidence and action
Evidence does not dictate implementation. Despite evidence and recommendations, several countries have not implemented screening. [154] [155] [156] On the other hand, some types of screening have been implemented without high-quality evidence, eg, with iFOBT and colonoscopy. Although such decisions may be based on accuracy data and modeling studies, making it "unethical not to screen," it can become difficult to obtain evidence on these screening strategies in the future. 5 
| Altering conceptions of disease
One important question that was not addressed in the literature is the status and prestige of the disease and the means to prevent, detect, and treat it. The CRC is organ specific and can be detected with advanced technology. Accordingly, it has a high prestige to physicians. 157 Cancer also has a special position among diseases. 158 Screening changes the attention on and the conception of a disease.
It also alters the end of health care services, from avoiding death because of CRC to avoid development of tumors. 159 Therefore, screening against CRC may well increase its status.
Polyps are very frequent in the (older people) population, and they normally do not result in symptoms, disease, or death. With screening they become target of medical attention and treatment, ie, making them disease (protodisease and psudodisease). Previously serrated lesion of the colorectum were not considered to be significant, but are now considered to be precancers (preconditions for cancers). 160, 161 Making polyps subject to medical attention has been criticized for being a kind of medicalization. 162 Invitation to screening may also result in worries and in people seeing themselves as patients, 163 ie, changing their selfconception and contributing to the medicalization of ordinary phenomena. Also, as people who remove polyps/adenomas are followed up they become patients (every 1, 3, or 10 years).
Moreover, removal of premalignant conditions may be conceived of as a form of human enhancement and promote an ideal image of a human being. This may pave the way for other types of enhancements:
"we improve human beings by removing (normal) polyps (X), so why should we not improve human beings by doing Y?" This mode of reasoning is frequently referred to as "the slippery slope argument"
and is somewhat controversial. 164, 165 Having and removing polyps may change persons' self-conception, eg, their vulnerability on the one hand and their improved health status on the other ("the health certificate effect"). Moreover, a safety net of screening may also make people expose themselves to risks, ie, "moral hazard." 12 Hence, screening programs and conceptions of cancer may change conceptions of self and alter our ways of communicating. only covers the detection part of screening and would be misleading.
Calling it a "cancer prevention screening program" may be more formally correct, but people would probably think that it detects cancers early. Calling it a "polyp resection program" would be more correct, but would probably not promote a high uptake. Hence, the name is more than a formality, as the choice will determine the measures for the benefits and the harms. A polyp resection program may have zero (cancer) overdiagnosis, as (almost) no cancer diagnosis is made. Polyps are detected and resected. However, a CRC screening program may have significant overdiagnosis, contrary to what it is considered to be today. 21 
| Some legal aspects
It has been pointed out in the literature that introducing screening legislation has been shown not to have any clear impact on disease incidence (in reduction) 166 and that CRC screening touches on legal provisions regarding confidentiality of patients and other human rights issues. 151 3.14 | Cut-offs and incidental findings
One of the identified challenges is to decide on cut-off values, 34, 167 eg, for polyp size. Removing very-low-risk polyps at a small, but real risk may be morally challenging.
A related problem is return of incidental findings. Several of the methods may find other health-related problems, and how to handle these may result in moral dilemmas.
| DISCUSSION
This review has identified a wide range of ethical issues. Some are related to basic ethical principles, such as autonomy, beneficence, nonmaleficence, and justice while others connect to basic concepts for health care, such as disease. Yet others connect to societal aspects, such as medicalization and overtreatment.
It is difficult to stop screening when you have started, and disinvestments are hard to make. 168, 169 Hence, thorough assessment appears to be warranted. It may be possible to state specific aims, and if these aims are not achieved in a given time frame, the program will be terminated.
Although some ethical issues are extensively discussed in the literature, such as informed consent, it does not necessarily mean that informed consent is a particularly challenging issue with CRC screening, as the many references may stem from informed consent has obtained much attention in general.
A wide range of relevant related issues have not been addressed in this review, eg, issues specific to emerging (biomarker or imaging) tests for CRC and the relationship between CRC and other (genetic) diseases, such as Lynch syndrome. Although such issues obviously raise a series of ethically relevant questions, they are beyond the scope of this review.
Some issues appear rather technical, eg, whether to assess and inform about screening programs on the basis of relative or absolute CRC risk reduction. 170, 171 However, such questions have strong moral bearings, which it is important to acknowledge in order to facilitate an open and transparent deliberation. Informing the public that CRC screening reduces mortality (in general) may be misleading. 79 Most of the identified ethical issues are covered by the questions of the axiological method, 6 but not all, eg, some of the practical challenges are not explicitly included in the questions. Moreover, several of the questions address issues not found in the literature, eg, whether it affects religious convictions, and whether screening would increase the status and prestige of the disease. Other methods for addressing ethical issues 172 could of course have been applied.
However, this review has identified a series of other ethical issues than previous studies 5 and is in line with other studies on ethics in screening.
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From exposing and elucidating the relevant ethical issues one would ask for specific recommendations. Should we implement CRC screening, or not? If yes, what kind of screening program? As these questions have to be answered in context, this review only provides input for the contextual decision-making process. In the same manner as evidence does not dictate implementation, [154] [155] [156] neither does a review of the ethical issues, ie, there is no ethical "imperative of evidence." Nonetheless, the review can prepare and facilitate this process.
| CONCLUSION
This review has identified a wide range of important ethical issues.
First and foremost, it has revealed how complex CRC screening is and how difficult this makes a utilitarian analysis of benefits and harms.
While predictive CRC screening poses problems with false test results and overdiagnosis, preventive screening proffers problems with overdetection and overtreatment. All screening presents potential harms because of the procedures, such as bleeding, perforation, and (seldom) death. These issues have to be balanced against the benefits of screening, such as reduced relative mortality and incidence rate.
Moreover, the question of participants' choice (autonomy) emerges as important. So do challenges with informing about screening in a manner that promotes and assures informed choice and at the same time reinforces uptake. Assuring equal access, equity in uptake, and justice surface as important ethical issues, eg, in the question of which groups should be offered which screening (age, sex, and risk class). Reaching the underserved is a core issue.
Societal issues, such as medicalization of ordinary conditions, changing the conception of disease, medicalization, and paving the way for enhancement, are also relevant.
In utilitarian terms the crucial moral question is whether it is right to perform 5700 colonoscopies, of which 11 will have their colon perforated, 914 will have moderate or severe abdominal pain, 2860 will have polyps removed unnecessarily, and 0 to 1 will die, to prevent 157 to die from CRC for every 100 000 persons invited, without reducing the overall mortality rate. 
